{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:50:07Z","timestamp":1793350207049,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-coi240046-4\"><jats:title>Importance<\/jats:title><jats:p>Prostate-specific membrane antigen (PSMA) demonstrates overexpression in prostate cancer and correlates with tumor aggressiveness. PSMA positron emission tomography (PET) is superior to conventional imaging for the metastatic staging of prostate cancer per current research but studies of second-generation PSMA PET radioligands for locoregional staging are limited.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240046-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the accuracy of fluorine-18 PSMA-1007 PET\/computed tomography (<jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT) compared to multiparametric magnetic resonance imaging (MRI) in the primary locoregional staging of intermediate-risk and high-risk prostate cancers.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240046-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Next Generation Trial was a phase 2 prospective validating paired cohort study assessing the accuracy of <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT and MRI for locoregional staging of prostate cancer, with results of histopathologic examination as the reference standard comparator. Radiologists, nuclear medicine physicians, and pathologists were blinded to preoperative clinical, pathology, and imaging data. Patients underwent all imaging studies and radical prostatectomies at 2 tertiary care hospitals in Alberta, Canada. Eligible participants included men with intermediate-risk or high-risk prostate cancer who consented to radical prostatectomy. Participants who underwent radical prostatectomy were included in the final analysis. Patients were recruited between March 2022 and June 2023, and data analysis occurred between July 2023 and December 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240046-7\"><jats:title>Exposures<\/jats:title><jats:p>All participants underwent both <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT and MRI within 2 weeks of one another and before radical prostatectomy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240046-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the correct identification of the prostate cancer tumor stage by each imaging test. The secondary outcomes were correct identification of the dominant nodule, laterality, extracapsular extension, and seminal vesical invasion.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240046-9\"><jats:title>Results<\/jats:title><jats:p>Of 150 eligible men with prostate cancer, 134 patients ultimately underwent radical prostatectomy (mean [SD] age at prostatectomy, 62.0 [5.7] years). PSMA PET was superior to MRI for the accurate identification of the final pathological tumor stage (61 [45%] vs 38 [28%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.003). PSMA PET was also superior to MRI for the correct identification of the dominant nodule (126 [94%] vs 112 [83%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.01), laterality (86 [64%] vs 60 [44%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.001), and extracapsular extension (100 [75%] vs 84 [63%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.01), but not for seminal vesicle invasion (122 [91%] vs 115 [85%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.07).<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi240046-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this phase 2 prospective validating paired cohort study, <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT was superior to MRI for the locoregional staging of prostate cancer. These findings support PSMA PET in the preoperative workflow of intermediate-risk and high-risk tumors.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.3196","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T16:30:40Z","timestamp":1719851440000},"page":"1097","source":"Crossref","is-referenced-by-count":45,"title":["Fluorine-18 Prostate-Specific Membrane Antigen\u20131007 PET\/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer"],"prefix":"10.1001","volume":"10","author":[{"given":"Nikhile","family":"Mookerji","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Pfanner","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaris","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guocheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Albers","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Broomfield","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Dean","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Alberta Centre for Urologic Research and Excellence (ACURE), Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"St. Martin","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Alberta Centre for Urologic Research and Excellence (ACURE), Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels-Erik","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Alberta Centre for Urologic Research and Excellence (ACURE), Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Evans","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Alberta Centre for Urologic Research and Excellence (ACURE), Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Abele","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dromparis","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joema Felipe","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Bismar","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Alberta Prostate Cancer Research Initiative (APCaRI), Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Michelakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Sutendra","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Cancer Research Institute of Northern Alberta (CRINA), Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wuest","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of Northern Alberta (CRINA), Edmonton, Alberta, Canada"},{"name":"Department of Oncology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tamm","sequence":"additional","affiliation":[{"name":"Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Alberta Prostate Cancer Research Initiative (APCaRI), Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kinnaird","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Alberta Centre for Urologic Research and Excellence (ACURE), Alberta, Canada"},{"name":"Alberta Prostate Cancer Research Initiative (APCaRI), Alberta, Canada"},{"name":"Cancer Research Institute of Northern Alberta (CRINA), Edmonton, Alberta, Canada"},{"name":"Department of Oncology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi240046r1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2214\/AJR.09.2527","article-title":"Imaging localized prostate cancer: current approaches and new developments.","volume":"192","author":"Turkbey","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"coi240046r2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5489\/cuaj.7832","article-title":"UPDATE\u20142022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging\u2014summary of changes.","volume":"16","author":"Mason","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"coi240046r3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management.","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"4","key":"coi240046r4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer\u2014part 1: screening, diagnosis, and local treatment with curative intent.","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"coi240046r5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial.","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"coi240046r6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis.","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"8","key":"coi240046r7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"coi240046r8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10231","key":"coi240046r9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"coi240046r10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"coi240046r11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41391-020-00292-2","article-title":"Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.","volume":"24","author":"Priv\u00e9","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"coi240046r12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.euo.2023.04.006","article-title":"Head-to-head comparison of 18F-PSMA-1007 positron emission tomography\/computed tomography and multiparametric magnetic resonance imaging with whole-mount histopathology as reference in localisation and staging of primary prostate cancer.","volume":"6","author":"Exterkate","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"coi240046r13","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"coi240046r14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2.","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"coi240046r16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer.","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"coi240046r17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis.","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"coi240046r18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial.","volume":"63","author":"Sonni","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"coi240046r19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/bco2.v3.1","article-title":"Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy.","volume":"3","author":"Vis","year":"2021","journal-title":"BJUI Compass"},{"issue":"6","key":"coi240046r21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/iju5.v6.6","article-title":"Gleason grade group 4 prostate biopsy with no cancer seen on final pathology in the magnetic resonance imaging and prostate specific membrane antigen-positron emission tomography era.","volume":"6","author":"Mookerji","year":"2023","journal-title":"IJU Case Rep"},{"key":"coi240046r15","volume-title":"American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual","author":"Edge","year":"2010","edition":"7th ed"},{"key":"coi240046r20","volume-title":"American Joint Committee on Cancer (AJCC)","author":"Amin","year":"2017","edition":"8th ed"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2820678\/jamaoncology_mookerji_2024_oi_240046_1723659863.18681.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:02:11Z","timestamp":1723734131000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2820678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.3196","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}